Sanofi sues to protect Lantus

Share this article:

Sanofi has filed a patent lawsuit against Eli Lilly, putting in place a 30-day waiting period for Eli Lilly's Lantus biosimilar.

The lawsuit is not a surprise: Lilly indicated in last week's earnings call that it was expected, because filing its FDA generics review application opened up a notification window, which alerted Sanofi that a potential competitor was on the block. It also put in place a stay that keeps Lilly's drug from progressing through the regulatory pathway.

Sanofi's suit comes with good reason—the diabetes medication earned the company almost $2 billion in third-quarter sales. In 2012, this same drug added just under $7 billion to its global coffers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.